Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases.

Hossein Jadvar, Susan G Groshen, David I Quinn

Abstract readLetterComment

In one paragraph

Article in Radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.Prostate cancer and prostatic diseases · 2021
Article
Case of prostate stromal tumour of uncertain malignant potential where positron emission tomography with 18F-fluorodeoxyglucose was useful for surgical planning.BMJ case reports · 2020
Article
Therapeutic efficacy, prognostic variables and clinical outcome ofThe British journal of radiology · 2019
Article
Is There Use for FDG-PET in Prostate Cancer?Seminars in nuclear medicine · 2016
Review
PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
Review

4 · The record

Corrections and comments

Commented on by
Response.2015
Comment on
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.2014

5 · Who and what money

Authors and funding

3 authors.

Hossein JadvarDepartments of Radiology (H.J.), Preventive Medicine (S.G.G.), and Medicine (D.I.Q.), Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033.

Susan G Groshen

David I Quinn

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026

$181.4M

FDG PET-CT in Metastatic Prostate CancerR01CA111613 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2005 to 2010

$2.5M

NCI NIH HHS P30-CA014089NCI NIH HHS R01-CA111613

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multimodal ImagingTomography, X-Ray ComputedBone NeoplasmsHumansMaleProstatic NeoplasmsReceptors, AndrogenReceptors, Androgen

Identifiers

PMID25625748

DOI10.1148/radiol.14141593

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.